Verve Therapeutics (VERV) said Friday it has named Troy Lister as chief scientific officer, starting June 21.
Lister, presently senior vice president of research and early development at the company, will replace Andrew Bellinger, who is stepping down but will continue to serve in an advisory capacity, the company said.
Price: 5.13, Change: -0.01, Percent Change: -0.19
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments